Show simple item record

dc.contributor.authorKlee, Jan L.
dc.contributor.authorKiliaan, Amanda J.
dc.contributor.authorLipponen, Arto
dc.contributor.authorBattaglia, Francesco P.
dc.date.accessioned2020-09-21T14:15:48Z
dc.date.available2020-09-21T14:15:48Z
dc.date.issued2020
dc.identifier.citationKlee, J. L., Kiliaan, A. J., Lipponen, A., & Battaglia, F. P. (2020). Reduced firing rates of pyramidal cells in the frontal cortex of APP/PS1 can be restored by acute treatment with levetiracetam. <i>Neurobiology of Aging</i>, <i>96</i>, 79-86. <a href="https://doi.org/10.1016/j.neurobiolaging.2020.08.013" target="_blank">https://doi.org/10.1016/j.neurobiolaging.2020.08.013</a>
dc.identifier.otherCONVID_41867727
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/71829
dc.description.abstractIn recent years aberrant neural oscillations in various cortical areas have emerged as a common physiological hallmark across mouse models of amyloid pathology and patients with Alzheimer's disease. However, much less is known about the underlying effect of amyloid pathology on single cell activity. Here, we used high density silicon probe recordings from frontal cortex area of 9 months old APP/PS1 mice to show that Local Field Potential (LFP) power in the theta and beta band is increased in transgenic animals, while single cell firing rates, specifically of putative pyramidal cells, are significantly reduced. At the same time, these sparsely firing pyramidal cells phase-lock their spiking activity more strongly to the ongoing theta and beta rhythms. Furthermore, we demonstrated that the anti-epileptic drug, levetiracetam, counteracts these effects by increasing pyramidal cell firing rates in APP/PS1 mice and uncoupling pyramidal cells and interneurons. Overall, our results highlight reduced firing rates of cortical pyramidal cells as a pathophysiological phenotype in APP/PS1 mice and indicate a potentially beneficial effect of acute levetiracetam treatment.en
dc.format.mimetypeapplication/pdf
dc.languageeng
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesNeurobiology of Aging
dc.rightsCC BY-NC-ND 4.0
dc.subject.otheramyloid
dc.subject.otherlocal field potential (LFP)
dc.subject.othersingle cell
dc.subject.otherfiring rate
dc.subject.othermouse model
dc.subject.otherAlzheimer’s disease
dc.titleReduced firing rates of pyramidal cells in the frontal cortex of APP/PS1 can be restored by acute treatment with levetiracetam
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202009215912
dc.contributor.laitosPsykologian laitosfi
dc.contributor.laitosDepartment of Psychologyen
dc.contributor.oppiainePsykologiafi
dc.contributor.oppiainePsychologyen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange79-86
dc.relation.issn0197-4580
dc.relation.volume96
dc.type.versionacceptedVersion
dc.rights.copyright© 2020 Elsevier
dc.rights.accesslevelopenAccessfi
dc.subject.ysoAlzheimerin tauti
dc.subject.ysoamyloidoosi
dc.subject.ysohermosolut
dc.subject.ysopatofysiologia
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p8412
jyx.subject.urihttp://www.yso.fi/onto/yso/p5248
jyx.subject.urihttp://www.yso.fi/onto/yso/p18309
jyx.subject.urihttp://www.yso.fi/onto/yso/p11545
dc.rights.urlhttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.relation.doi10.1016/j.neurobiolaging.2020.08.013
jyx.fundinginformationThe study was supported by the Säätiöiden post doc -pooli (The Finnish Cultural Foundation) to Dr. Arto Lipponen. Silicon probes were manufactured by IMEC (Leuven, Belgium) with funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement nr. 600925 (NeuroSeeker).
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY-NC-ND 4.0
Except where otherwise noted, this item's license is described as CC BY-NC-ND 4.0